Clinical Trial Update: A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of TransCon TLR7/8 agonist with or without pembrolizumab in patients with advanced or metastatic solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Hpv-associated Cancers
• Melanoma
• Solid Tumors

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TransCon TLR7/8 Agonist

Snippet

Sponsor: Ascendis Pharma Oncology Division A/S | Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED